Kenvue (NYSE:KVUE) Receives New Coverage from Analysts at Jefferies Financial Group

Analysts at Jefferies Financial Group assumed coverage on shares of Kenvue (NYSE:KVUE) in a report issued on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $27.00 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 17.26% from the stock’s previous close.

KVUE has been the topic of a number of other research reports. Piper Sandler upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday. UBS Group upped their price objective on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Citigroup decreased their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Royal Bank of Canada lowered Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a research report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $22.10.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.03 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $23.55. The business has a 50 day moving average price of $21.21 and a two-hundred day moving average price of $20.03. The firm has a market cap of $44.10 billion, a PE ratio of 29.52, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The business had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business’s revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Sell-side analysts expect that Kenvue will post 1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kenvue

Several institutional investors have recently modified their holdings of KVUE. Assetmark Inc. lifted its position in Kenvue by 2,337.2% in the 4th quarter. Assetmark Inc. now owns 39,995 shares of the company’s stock valued at $861,000 after purchasing an additional 38,354 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Kenvue by 69.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,326 shares of the company’s stock valued at $50,000 after buying an additional 954 shares during the last quarter. US Bancorp DE boosted its position in shares of Kenvue by 111.7% during the fourth quarter. US Bancorp DE now owns 103,733 shares of the company’s stock worth $2,233,000 after buying an additional 54,729 shares during the period. SageView Advisory Group LLC bought a new position in Kenvue in the 4th quarter worth approximately $262,000. Finally, Parallel Advisors LLC grew its holdings in Kenvue by 75.4% in the 4th quarter. Parallel Advisors LLC now owns 18,182 shares of the company’s stock worth $391,000 after buying an additional 7,818 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.